ARTICLE | Company News
FDA approves Adcetris for first-line classical Hodgkin's lymphoma
March 20, 2018 10:16 PM UTC
FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin in combination with chemotherapy to treat adults with previously untreated stage III or IV classical Hodgkin's lymphoma. The company said it is FDA's first approval for the first-line indication in more than 40 years. The approval comes six weeks ahead of the drug's May 1 PDUFA date.
A Seattle Genetics spokesperson told BioCentury the company plans to launch Adcetris "immediately." According to the spokesperson, the average cost per patient for a full course of first-line therapy will be about $135,000 with discounts and rebates...
BCIQ Target Profiles